Digital healthcare specialist SCL Science announced on the 14th that its sales revenue last year reached 4.7 billion KRW, a 258% increase compared to the previous year.
Last year's external growth was driven by the strong performance of the bio-logistics division, which delivers bio materials, pharmaceuticals, and medical devices. The company provides accurate and safe bio-logistics services using advanced technology-based cold chains such as the Internet of Things (IoT).
Based on its stable bio-logistics business, SCL Science plans to start sales of the in-body hemostatic product ‘Inoseal Plus DL’ in the second half of this year. Unlike the class 2 medical device category for external hemostatic products, in-body hemostatic products are classified as high-risk class 4 medical devices, commanding sales prices approximately 10 times higher than class 2 products.
The company is also progressing with contracts for next-generation IT development projects signed with Hanaro Medical Foundation in January and a central lab (C-LAB) management system development service contract with SCL Healthcare. Through these, it plans to secure a stable revenue base and expand its business scope to external customers across each digital platform business division.
Efforts are also focused on discovering new business pipelines and strengthening competitiveness. In particular, SCL Science has established various collaborative systems, including joint translational medicine research with the Korea Advanced Institute of Science and Technology (KAIST) to develop AI-based new drug candidates utilizing the vast data of the SCL Group.
A company representative stated, “Last year’s high sales growth resolved the management item issue and laid the foundation for a turnaround this year. We will maximize corporate value through stable operation of our cash cow business and strengthening digital and bio-platform businesses.”
On the 5th, SCL Science approved an agenda at the extraordinary general meeting of shareholders for a comprehensive stock exchange to make specimen analysis specialist SCL Healthcare a wholly owned subsidiary. SCL Healthcare recorded sales of 14.6 billion KRW and operating profit of 700 million KRW in 2023, and its results will be reflected in consolidated financials starting from the second quarter of this year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
